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Introduction
Mucins are high molecular mass O-glycosylated pro-
teins (50-80% of their mass is due to O-linked carbohy-
drate chains) which can be divided into membrane
bound and secreted [1]. They are expressed by various
epithelial cell types having a central role in the protec-
tion, lubrication and acid resistance of the epithelial sur-
face and, therefore, in promoting cell survival in vari-
able conditions. However, alterations in mucins expres-
sion profile have been long implicated in several animal
and human diseases, especially in malignant transfor-
mation. At least nineteen mucin genes have been report-
ed to date. The secretory mucins include MUC2,
MUC5B, MUC5AC, MUC6, MUC7, MUC8, MUC9
and MUC19 while the membrane bound comprise
MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13,
MUC15, MUC16, MUC17 and MUC20 [2-4]. 
MUC1 is a transmembrane mucin expressed on the
apical surface of most epithelia. Full length MUC1 is
synthesized as a single polypeptide chain, which
undergoes an early proteolytic cleavage, creating two
subunits that remain associated during its post-transla-
tional processing and transport to the cell surface [5].
Supposedly, the heterodimeric existence of MUC1
may provide a mechanism for rapid shedding of the
extracellular domain [1]. The large fragment contains
most of the extracellular domain while the smaller sub-
unit consists of a short extracellular domain, a trans-
membrane domain and a tyrosine-phosphorylated
cytoplasmic tail (CT) of 72 aminoacids [1,5,6]. The
proposed functions for MUC1 include modulation of
cell adhesion, signal transduction in which CT is
involved, lubrication and hydration of epithelial sur-
faces as well as their protection from infection [7-10]. 
Although the expression of transmembrane mucins
was originally thought to be restricted to epithelial tis-
sues, in a recent study MUC4 was detected in three
types of endothelial cell lines, among others of
HUVECs [11]. Additionally, the expression of MUC1
mRNA was observed by RT-PCR in the human corneal
endothelium, like MUC1 protein, on the apical surface
of these cells and at the superficial layer of the cyto-
plasm in an immunohistochemical study [12]. MUC1
mRNA and protein expression was also find in pul-
monary vascular endothelial cells [13]. Our preliminary
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experiments indicated the presence of MUC1 glyco-
protein in culture medium of HUVE cells. As we were
surprised to find MUC1 protein expression in endothe-
lial cells, we decided to investigate transmembrane
MUC1 mucin biosynthesis in human umbilical vein
endothelial cells (HUVECs) in culture. Since up to now
there have been only a few publications concerning
MUC1 mucin expression in endothelial cells, we exam-
ined this expression using three different methods:
Western blotting, flow cytometry and quantitative
measurement of incorporated radioactivity. The pres-
ence of MUC1 on the surface of HUVE cells, and the
possible participation of carbohydrate epitopes of
MUC1 as ligands on this surface have not been yet
demonstrated.
Materials and methods
Materials. [6-3H]-Glucosamine hydrochloride (specific activity 
24 Ci/mmol; 888 GBq/mmol) was from PerkinElmer Life
Sciences, Inc. TNF-α, IFN-γ, collagen I, SDS, protease inhibitor
cocktail, secondary antibody conjugated with horseradish peroxi-
dase, 4-chloro-1-naphtol, ABTS liquid substrate system, trypan
blue, culture media were purchased from Sigma-Aldrich Co.
(USA). Monoclonal anti-MUC1 antibody (clone MAb 4058) was
from Chemicon International; monoclonal anti-β-actin antibody
was the product of Santa Cruz Biotechnology Inc. Monoclonal
anti-MUC1 antibody conjugated with fluorescein isotiocyanate
(HMPV-FITC), IgG1-FITC isotype control and fibronectin-coated
96-well plates were purchased from BD Pharmingen; Immobilon-
P membrane was from Millipore (USA); 25 and 75 cm2 culture
flasks coated with fibronectin were from Nalge Nunc Internation-
al Inc. (USA) and 96-well microtitre plates were from Nunc (Den-
mark); BCA Protein Assay Kit was from Pierce (USA). Polyacry-
lamide gradient gels 4-12% were from Lonza. Biotinylated lectins
(Maccia amurensis -MAA and Arachis hypogaea -PNA) and strep-
tavidin-HRP conjugate were from Vector Labs. EC10 blocker of
α2β1 integrin and VLO4 disintegrin, specibfic inhibitor of α5β1
integrin, were kindly provided by Dr. C. Marcinkiewicz from Tem-
ple University (Philadelphia, USA). All other chemicals were of
analytical grade purity from commercial sources.
Cell cultures. Endothelial cells were isolated from human umbili-
cal vein by treatment with collagenase (1 mg/ml) for 10 min at
37°C and the obtained suspension was then centrifuged at 2,500
rpm for 10 min at room temperature. The cells were cultured in 75
cm2 flasks coated with fibronectin, in M199 medium supplement-
ed with 20% fetal bovine serum, penicillin G (100 IU/ml), strepto-
mycin (100 μg/ml), amphotericin B (0.25 μg/ml), heparin (100
μg/ml), ECGS (200 μg/ml) and Hepes (25 mmol/l) at 37°C in a 5%
CO2 and 95% air incubator. Subconfluent cells (above 90% of con-
fluency) were detached with 0.1% trypsin in serum-free M199
medium, counted and inoculated at about 106 cells per 25 cm2
flask. The HUVEC cultures were characterized by differential
immunocytochemical staining to confirm their purity. More than
95% of the cells stained positively with antibodies against von
Willebrand factor. The cells within 3-4 passages were used for the
experiments. After reaching 80% of confluence, the cells were
treated with one of the following: TNF-α (40 ng/ml) or IFN-γ (40
ng/ml); or TNF-α together with IFN-γ (both at 40 ng/ml) for 48 h.
In some experiments, labeling with [3H]glucosamine (20
μCi/flask) was performed during the last 24 h when cells were des-
tined for quantitative determination of MUC1 mucin.
Preparation of cell lysates and culture media. The cell layer was
washed with phosphate buffered saline (PBS), harvested by scrap-
ing and centrifuged (4,000 rpm, 10 min). The media and cell wash-
ings were combined for determination of MUC1 shedding level.
MUC1 mucin was isolated from culture media by exclusion chro-
matography on Bio-Gel A-0.5m column, as previously described
[14]. The cells were homogenized in an ice bath using sonification
(3 times for 15 sec; 50 Hz) in 0.5 ml of lysis buffer (50 mM
Tris/HCl pH 7.5, containing 1 mM EDTA and protease inhibitor
cocktail), then 0.5 ml of lysis buffer, containing Nonidet P-40, was
added (final concentration of detergent was 1%). The homogenate
was incubated in an ice bath for 1 h, centrifuged at 16,000 rpm for
30 min, and the supernatant was used as lysate for further determi-
nations. Cells for the adhesion test were harvested using a different
method described below.
Protein concentration in culture media and cell lysates was
determined by the bicynchonic acid method according to the man-
ufacturer's description.
SDS-PAGE and Western blotting. Equal amounts of cellular pro-
tein (30-50 μg) were submitted to electrophoresis on gradient SDS-
polyacrylamide gels (4-12%), according to the Laemmli method
[15]. Pre-stained high molecular weight protein markers (range
29,000-205,000 Da) were used as standards. After electrophoresis,
the proteins were electrotransferred onto PVDF membranes
(Immobilon-P) in a buffer consisting of 25 mM Tris, 192 mM
glycine and 20% methanol, pH 8.4, for 2 h at constant voltage (100
V) with cooling. Membranes were blocked with 3% skim milk
overnight, then incubated with anti-MUC1 MAb (MAb 4058,
1:500) for 2 h. Membranes were washed and incubated with anti-
mouse IgG antibody conjugated with peroxidase, then color was
developed by the use of 4-chloro-1-naphtol reagent.
Quantitative determination of MUC1 by measurement of
incorporated [3H]glucosamine. The lysates of metabolically
labeled cells were submitted to exclusion chromatography on Bio-
Gel A-0.5m columns as previously described [14]. The concentrat-
ed high molecular weight fraction of cell lysates was separated by
SDS-PAGE and then quantitative determination of MUC1 radioac-
tivity was performed according to Yan i Sohal [16]. The fragments
of gel, equivalent to respective protein lanes, were cut onto 1.0 cm
wide pieces. Each of them was dried, dissolved in 1 ml of 30%
H2O2 and the radioactivity of [3H] was measured in a scintillation
counter.
Cell-surface ELISA. Human umbilical vein endothelial cells
(HUVEC) ELISA was performed according to the method
described by Strindhall et al. [17], with some modifications.
Briefly, cells were grown in M199 medium in 96-well microtitre
plates to a confluent cobblestone-like monolayer, and then incu-
bated with TNF-α (40 ng/ml) for different periods of time (0, 2, 6
and 18 h). They were washed once with PBS and fixed with 0.1%
formaldehyde/PBS for 10 min at room temperature. After two
washes with PBS, the cells were incubated with PBS/5% BSA for
1 h at room temperature or overnight at 4°C to block nonspecific
binding sites. The cells were washed once with PBS/0.05% Tween
20 and once with PBS and then incubated with anti-MUC1 primary
antibody (MAb 4058) at a 1:400 dilution in PBS/1% BSA for 2 h
at 37°C with gentle rocking. Then, they were washed twice with
PBS and once with PBS/0.05% Tween 20 and incubated with sec-
ondary antibody conjugated with horseradish peroxidase at a dilu-
tion of 1:1000 in PBS/1% BSA for 2 h at room temperature with
gentle rocking. Detection was performed by using ABTS reagent
as a substrate. Color development was measured as the absorbance
at 405 nm using ELISA-reader (Sunrise, Tecan). 
Some carbohydrate structures on HUVECs were detected by
ELLA (enzyme-linked lectin assay) which was performed as above
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described, but instead of monoclonal antibodies, biotinylated lectins
were used: from Maccia amurensis (MAA) to recognize α2,3 linked
sialic acid and from Arachis hypogaea (PNA) to detect T antigen
(Galβ1-3GalNAcα1-O-Ser/Thr). Cells were incubated for 2 h with
biotinylated-PNA or -MAA, both at 20 μg/ml, before being washed
and incubated for 1 h with streptavidin-HRP conjugate at 5 μg/ml.
The remaining protocol of detection was the same as for the reaction
with monoclonal antibody. Before treatment with PNA lectin, the
cells were incubated with Vibrio cholerae neuraminidase (15
mU/ml, 1.5 h) in order to remove terminal sialic acid residues. 
Flow cytometry. Cells were detached from tissue culture flasks with
0.2% EDTA in PBS, pH 7.4 and washed in PBS containing 1% BSA
and 0.1% NaN3 (PBS/1% BSA). To determine MUC1 expression on
cell surface, the detached cells were incubated with fluorescein iso-
tiocyanate (FITC)-conjugated mouse anti-human MUC1 monoclon-
al antibody, according to the method described for Ishikawa cell line
in our earlier study [18]. Mouse IgG1-FITC antibody was used as 
a negative control. After washing, the cells were analyzed for fluo-
rescence intensity by flow cytometry (Coulter Epics XL). 
Cell adhesion assay. Adhesion assay was performed with control
and TNF-α stimulated cells, according to the method described ear-
lier [18]. Fibronectin coated plates (BD Pharmingen, 96-well) and
plates coated with collagen type I (100 μg/ml) were blocked for 90
min at 37°C with 1% heat-denatured BSA. Cells for adhesion assay
were scraped off, washed in serum-free medium and re-seeded at a
density of 5 × 104 cells/well on collagen or fibronectin. They were
allowed to adhere for 60 min at 37°C. Non-adherent cells were
removed by washing 3 times with PBS, whereas adherent cells were
stained with 0.1 % crystal violet for 30 min, washed in tap water and
air dried. Stained cells were lyzed overnight in 0.1% Triton X-100 to
release the dye. The absorbance at 620 nm determined using an
ELISA-reader (Sunrise, Tecan) was proportional to cell number.
Each data point was calculated from two separate experiments per-
formed in quadruplicate and was expressed as the mean±standard
deviation (SD). Nonspecific cell adhesion as measured on BSA-
coated wells was subtracted.
In order to determine the effect of the inflammatory cytokine
on HUVE cells adhesion to ECM proteins (collagen I and
fibronectin) the cells were treated for 6 hours with increasing doses
(10 and 40 ng/ml) of TNF-α. Non-treated cells served as a control.
Assay of MUC1 influence on cell adhesion. To test the effect of
MUC1 on HUVE cells adhesion to fibronectin or collagen type I,
a part of cell suspension was preincubated with anti-MUC1 MAb
4058 (1:25 diluted), and added to each well (5 × 104 cells/well) in
quadruplicate. Further procedure was the same as described above
for the adhesion test. Results were expressed as a percentage of OD
value of cells with antibody in comparison to OD of cells without
antibody.
Assay of integrins effect on cell adhesion. To test the effect of
α5β1 integrin on cell adhesion to fibronectin a part of cell suspen-
sion was preincubated with VLO4 disintegrin (2 mg/0.1 ml), which
is a potent and selective in vitro inhibitor of α5β1 integrin [19],
then added to each fibronectin-coated well (5 × 104 cells/well) in
quadruplicate. The effect of α2β1 integrin on cell adhesion to col-
lagen type I was examined in the same conditions with EC10 
(2 mg/0.1 ml), a specific blocker of this integrin [20]. A further
procedure of cell adhesion assay was the same as described above.
Results were expressed as a percentage of OD value of cells with
antibody in comparison to OD of cells without inhibitor.
Ethical issues. The study was approved by the Committee for
Ethics and Supervision on Human and Animal Research, Medical
University of Bia³ystok, with informed consent from the patients.
Statistical analysis. The results were subjected to statistical analy-
sis by Statistica 6.0 PL program. Data are represented as mean±SD.
Normal distribution of data was assessed by the Kolmogorov-
Smirnov test. Since the values met the criteria of a normal distri-
bution the results were submitted to statistical analysis with the use
of Student's t-test, accepting p 0.05 as significant.
Results 
Western blotting detection of MUC1 in
HUVECs
To probe for the expression of MUC1 mucin in
HUVECs, the lysates were obtained by cells sonifica-
tion, then the incubation with lysing buffer and this
material was used for electrophoresis. To test the pres-
ence of soluble secreted/shed MUC1 form in the
growth medium, the culture medium was concentrat-
ed, pre-purified on Bio-Gel A-0.5m column and high
molecular weight fraction, dot-blot valuated for
MUC1 presence, was used for electrophoresis. Elec-
troblotting and detection of MUC1 antigens with MAb
4058, specific to tandem repeat core of MUC1 protein,
confirmed the presence of MUC1 protein in lysates
and medium fractions. As shown in Fig. 1, cellular
medium contains MUC1 mucin in greater quantity
then lysate, and molecular weight of this protein is
higher in medium then in lysate. 
Effect of TNF-α and IFN-γ  on membrane
localization of MUC1 on HUVECs 
Earlier studies have shown that MUC1 biosynthesis in
multiple epithelial cell types can be stimulated by
TNF-α [21]. Therefore, searching for the factors
affecting MUC1 expression in endothelial cells, we
first applied TNF-α. Incubation of HUVECs with
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Fig. 1. Detection of MUC1 in lysate and medium of HUVEC.
Cells were cultured for 48 h then medium and lysate were elec-
trophoresed on 4-12% polyacrylamide gradient gels (Lonza), elec-
trotransfered onto PVDF membrane and immunodetected with
anti-MUC1 antibody (MAb 4058, 1:500). L- lysate; Lr- lysate in
reducing conditions; M-medium; Mr- medium in reducing condi-
tions.
TNF-α (40 ng/ml) at varying time intervals (2 h, 6 h or
18 h) has a small effect on membrane localization of
MUC1 protein, which was determined in a test similar
to ELISA, with monoclonal antibody (Table 1). In sim-
ilar test with lectins, specifically reacting with certain
carbohydrate structures, the incubation with TNF-α
was shown to have no effect on membrane T antigen
and resulted in a small decrease in the level of termi-
nal α2,3-linked sialic acid residues (Table 1). 
Taking into account the above results, we extended
incubation time with TNF-α to 48 h and, in addition,
IFN-γ was employed alone and in combination with
TNF-α. The expression of MUC1, in control untreated
cells and in cells treated with cytokines, was probed in
three different manners: Western blotting, flow cytom-
etry and metabolic labeling with measurement of gel
fragment radioactivity after SDS-PAGE. 
Detection of MUC1 antigens in cellular lysates was
performed by Western blotting with anti-MUC1 anti-
body (MAb 4058, specific to tandem repeat core of
MUC1 protein). As shown in Fig. 2A, both TNF-α and
IFN-γ significantly increased MUC1 protein expres-
sion in HUVE cells. Two MUC1 forms, with different
molecular masses: one exceeding 205 kDa and the
other 116 kDa are visible with a little change in band
position in the presence of TNF-α. The intensity of the
bands was quantified by densitometry analysis. As
shown by densitometry, about a 2-fold increase in
MUC1 expression was obtained following TNF-α
treatment, compared to constitutive MUC1 expression.
A smaller increase in MUC1 expression was observed
after treatment with IFN-γ alone (about 1.3-fold) and
in combination with TNF-α (about 1.5-fold).
To verify a quantitative assessment of cellular
MUC1 protein content and probe for the influence of
these cytokines, the cells were labeled with [3H]-glu-
cosamine. Radioactive labeled macromolecules from
cell lysates were analyzed by SDS-PAGE on precast 4-
12% gradient gels. The results obtained in this method
confirmed stimulating effect of TNF-α and IFN-γ on
MUC1 biosynthesis in HUVE cells (Fig. 2B). Based on
the results of radioactivity measurement it can be also
affirmed that TNF-α significantly increased MUC1
mucin glycosylation, since expression of MUC1 glyco-
form with high molecular mass above 205 kDa (on the
top of gel) was over 3-fold increased, compared with
this glycoform from control untreated cells. 
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Table 1. Effect of TNF-α on expression of membrane antigens
(MUC1, T antigen and α2,3-sialic acid) on HUVECs. HUVECs
were incubated with TNF-α (40 ng/ml) at varying time intervals
(2h, 6h, or 18h) and expression of particular structures was evalu-
ated in ELISA test. Values are the mean±SD of three distinct
experiments. *The results are significantly different (p<0.05) from
the untreated, control cells taken as 100%. 
Fig. 2. The influence of cytokines on MUC1 expression deter-
mined by Western blotting and radioactivity measurement. (A)
MUC1 expression determined by Western blotting: 1 – control
cells (untreated); 2 – cells treated with TNF-α (40 ng/ml); 3 –
treated with IFN-γ (40 ng/ml); 4 – treated with TNF-α together
with IFN-γ (both at 40 ng/ml); MW – high molecular mass protein
standards. The cells were incubated with cytokines for 48 h. Values
of MUC1 band intensity were measured by the use of SynGene
software. The intensity of MUC1 bands from lane 1 (control
untreated cells) was assumed as 1.0. The expression of β-actin
served as a control for protein loading. (B) Quantitative determi-
nation of MUC1 by measurement of radioactivity in the scraps of
polyacrylamide gel. Radioactivity of [3H]glucosamine incorporat-
ed to MUC1 areas from lane 1 (control untreated cells) was
assumed as 1.0 (for details see Material and methods section).
Data are shown as means from three independent experiments. 
*p<0.05, statistically significant differences compared with
untreated (control) cells.
Flow cytometry is a very reliable method to inves-
tigate MUC1 content in the cellular membrane. This
method confirmed the highest stimulatory effect of
TNF-α on MUC1 protein incorporation into the cell
membrane: 236% of stimulation was found. Similar to
the data obtained in densitometry, in the presence of
IFN-γ and combined action of TNF-α and IFN-γ, the
increase was lower, reaching 150% and 176%, respec-
tively, in comparison to control cells (Fig. 3).
Effect of TNF-α on cell adhesion to ECM pro-
teins (collagen and fibronectin)
To determine the effect of TNF-α on HUVE cells adhe-
sion to ECM proteins, the cells were treated for 6 h with
10 or 40 ng/ml of TNF-α and then adhesion test was
performed. As shown in Fig. 4A incubation with TNF-
α does not change the adhesion of HUVECs to colla-
gen type I in comparison to control cells. The employ-
ment of anti-MUC1 antibody caused increase in cells
adhesion to collagen type I in control and TNF-α treat-
ed cells, in the same extent (about 20%). In the pres-
ence of specific inhibitor of α2β1 integrin, EC10, adhe-
sion decreases similarly (about 30% compared to cells
without EC10) in all tested groups of cells (Fig. 4A).
Treatment with TNF-α slightly enhanced adhesion
of HUVECs to fibronectin, in a dose-dependent man-
ner, compared with control cells (9% and 17% of
increase). In the presence of anti-MUC1 antibody, the
adhesion of these cells to fibronectin increases about
7% (control cells), 6% (T1) and 10% (T2) compared to
cells without antibody. Disintegrin VLO4, the blocker
of α5β1 integrin, has a greater effect on adhesion of
cells incubated with TNF-α to fibronectin: adhesion
was decreased 11.5% and 20% , respectively for TNF-
α concentration 10 ng/ml and 40 ng/ml, compared to
cells without disintegrin (Fig. 4B).
Discussion
Membrane mucins are particularly important for pro-
viding a direct anti-adhesive barrier at the luminal sur-
faces of epithelia [22,23], protecting them against
invasion from noxious organisms. Endothelia of blood
vessels are a specialized form of epithelia, which have
many similar functions to other epithelia. However,
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Fig. 3. Flow cytometric analysis of cytokine
effect on the level of plasma-membrane-
localized MUC1 in HUVECs. (A) Represen-
tative flow-cytometry profiles (histograms):
1 – control cells (untreated); 2 – TNF-α-treat-
ed (40 ng/ml); 3 – IFN-γ-treated (40 ng/ml);
4 – treated with TNF-α together with IFN-γ
(both at 40 ng/ml). Cells were incubated with
cytokines for 48 h. Black areas define nega-
tive control. (B) Mean fluorescence intensity
(MFI). Average value of MFI in 5 independ-
ent experiments is shown. *The difference
between treated and control cells was statisti-
cally significant.
mucins of the MUC gene family have not been report-
ed to play important roles in endothelial cells, despite
of the fact that a non-adhesive luminal surface is criti-
cal in blood vessels. Instead, blood vessels are known
to contain an array of different glycoproteins at their
luminal surfaces [24]. Some of these, such as intercel-
lular cell adhesion molecule (ICAM) and von Wille-
brand factor (vWF), are involved in cell-cell adhesion
in the circulation [25]. Adhesion and anti-adhesion
molecules play, among others, an important role in the
interaction of tumor cells with vascular endothelial
cells during tumor invasion and metastasis [26]. Vas-
cular endothelial cells are also involved in angiogene-
sis, a critical process in wound-healing, inflammation,
cancer development and embriogenesis.
In this study, we demonstrated that in human
umbilical vein endothelial cells (HUVECs) MUC1
mucin protein can be synthesized and released/shed
from cellular membrane. Electrophoresis and Western
blotting analysis revealed transmembrane mucin
MUC1 in cell lysates and in culture medium of
HUVECs. Based on the results of Western blotting, it
can be claimed that MUC1 content in cellular medium
is higher than in lysate and that mucin glycoforms,
shed from cellular surface to medium, have greater
molecular mass, probably in the effect of more exten-
sive glycosylation, similarly to epithelial cells [27].
The quantitative assessment of MUC1 content in cell
lysate was performed by radioactivity measurement.
The presence of MUC1 on the surface of HUVE cells
was also confirmed by flow cytometry. 
In a number of epithelial cell types, including ovar-
ian carcinoma [28], hematopoietic [29] and prostate
tumor [21] cells, interferon-γ has been shown to pro-
mote expression of MUC1. Tumor necrosis factor-α
(TNF-α) is also able to upregulate MUC1 expression
in epithelial cells derived from airway, oral, breast,
prostate and uterine tissues [10,21,30-33]. In prostate
tumor cells [21], oral epithelial cells [31] and in nor-
mal breast epithelia and breast cancer cells [10], this
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Fig. 4. Effect of TNF-α on cell adhe-
sion to collagen type I (A) and to
fibronectin (B).
Cells were incubated with TNF-α at
concentrations of 10 and 40 ng/ml
(T1, T2, respectively, C – control,
non-stimulated cells) for 6 hours,
then adhesion test was performed
with anti-MUC1 MAb, with EC10
(for adhesion to collagen), with dis-
integrin VLO4 (for adhesion to
fibronectin), or without these agents.
Data are expressed as a mean (n =
4)±SD. *p<0.05, statistically signifi-
cant differences compared with non-
preincubated cells from each group.
effect has been shown to be synergistic with interfer-
on-α. For this reason, we decided to verify the effect
of these cytokines on MUC1 biosynthesis in endothe-
lial cells (HUVEC). Cytokines bind to specific recep-
tors to activate associated tyrosine kinases that initiate
downstream signaling. A signal transducer and activa-
tor of transcription (STAT) as well as nuclear factor
kappa B (NF-κB) response elements, located within
the MUC1 promoter, apparently mediate the transcrip-
tional induction of MUC1 by cytokines [10,34].
The expression of MUC1 on the surface of
HUVECs was almost unaltered during a short-time (2-
18 h) treatment with TNF-α, as measured by ELISA
test. The extension to 48 h of incubation time with
TNF-α resulted in an increase in the level of MUC1
antigen on the surface of cellular membrane (as meas-
ured by flow cytometry). The Western blotting method
detected an increase in the expression of both MUC1
glycoforms: with high molecular mass above 205 kDa
and with lower molecular mass (116-205 kDa). Addi-
tionally, a decrease in molecular mass of a smaller
MUC1 form was observed in the effect of TNF-α
treatment. The molecular mass of this glycoform was
unchanged after cell treatment with IFN-γ alone or
after combined action of these compounds. As proved
by the measurement of radioactivity of [3H]-glu-
cosamine, bound to mucin oligasaccharides, TNF-α
caused over a three-fold increase in the content of high
molecular mass MUC1 form, compared to about a 2-
fold increase shown by Western blotting, where MUC1
polypeptide chain was detected. A possible explana-
tion of this finding may be enhanced mucin glycosyla-
tion. We demonstrated a decrease in the level of sialic
acid on cell surface of HUVECs after TNF- treatment.
Since sialic acid residues are located on the non-reduc-
ing ends of glycoprotein oligosaccharide chains, there-
fore apparently longer oligosaccharide chains can be
synthesized due to reduction in sialic acid content. On
the contrary, T antigen content was not changed. It has
been shown previously that in carcinoma cells the
incomplete elongation of O-glycan saccharide chains
leads to the expression of shorter carbohydrate struc-
tures such as Tn, sialyl-Tn, or T antigens, which are
usually expressed on MUC1 mucin as their carbohy-
drate structures [35-37]. Thomsen-Friedenreich carbo-
hydrate antigen (Galβ1-3GalNAcα1-Ser/Thr – TF or T
antigen), observed on the surface of endothelial cells,
could play a role in the interactions of these cells with
galectin-3, similarly to cancer cells [38].
Poor effect of short-time treatment with TNF-α on
MUC1 expression was confirmed by adhesion test.
Adhesion of TNF-α-treated cells to collagen type I
was unchanged while adhesion to fibronectin was
slightly increased as compared to control cells. The
results of adhesion test with anti-MUC1 antibody and
with specific blockers of α2β1 and α5β1 integrins con-
firmed the presence of these membrane proteins on
HUVEC membrane surface. MUC1 mucin can exert
an anti-adhesion effect, caused by steric hindrance of
interactions between adhesion receptors and their lig-
ands, and therefore after blocking of mucin by a spe-
cific antibody, an increase in adhesion was observed.
On the other hand, blocking of adhesion receptors –
integrins, caused a decrease in adhesion to ECM pro-
teins. As a result of HUVEC treatment with TNF-α,
the expression of α2β1 was unaltered, since the reduc-
tion in adhesion after incubation with EC10 was the
same in control and cytokine treated cells. On the con-
trary, the expression of α5β1 integrin presumably rose
after cytokine treatment and therefore the effect of this
integrin blocking was higher in treated than in untreat-
ed cells.
In conclusion, we are the first to report that MUC1
transmembrane mucin is expressed in human umbili-
cal vein endothelial cells and could be shed from cell
surface to culture medium. We also show that mucin
expression is stimulated by proinflammatory
cytokines. These data indicate MUC1 presence on the
cellular membrane of endothelial cells although the
role of this glycoprotein in interactions with different
cell types in physiological and pathological processes
needs further investigations. 
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